EUVIMEDEUVIMED entdecken
Crossref

Subclinical B-type Natriuretic Peptide Elevation 24 Months After Anthracycline-Containing Chemotherapy

Tetsuya Tani, Masayoshi Oikawa, Himika Ohara, Daiki Yaegashi, Yu Sato, Tetsuro Yokokawa, Shunsuke Miura, Tomofumi Misaka, Akiomi Yoshihisa, Takafumi Ishida, Yasuchika Takeishi

International Heart Journal · 2025

DOI: 10.1536/ihj.24-293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Heart Journal, 2025. Verfasst von Tetsuya Tani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Fukushima Medical University. Hauptthemen laut MEDLINE: Natriuretic Peptide, Brain, Anthracyclines, Cardiotoxicity, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The incidence of anthracycline-induced cardiotoxicity typically occurs within the first year after chemotherapy, but the changes in cardiac function and biomarkers beyond this initial year have not been adequately investigated. We analyzed 105 consecutive patients followed for 24 months after anthracycline-containing chemotherapy at Fukushima Medical University Hospital from June 2018 to April 2021. Echocardiography and blood tests for cardiac troponin I and B-type natriuretic peptide (BNP) were conducted at baseline, and 3, 6, 12, and 24 months after chemotherapy initiation. In the whole patient cohort, BNP levels increased from 10.5 [6.3-18.3] pg/mL at baseline to 19.2 [12.1-34.5] pg/mL at 24 months after chemotherapy (P < 0.01). Based on BNP levels at 24 months, the patients were divided into 2 groups: a BNP-elevated group (n = 57) and a BNP-normal group (n = 48). In the BNP-elevated group, time-course changes revealed that BNP levels remained stable until 12 months, but increased at 24 months. Multivariate logistic analysis identified age, total anthracycline dose, and baseline BNP levels as predicting factors for elevated BNP levels at 24 months. Subclinical BNP elevation was observed at 24 months of follow-up after initiation of anthracycline-containing chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Natriuretic Peptide, BrainAnthracyclinesCardiotoxicityAntineoplastic AgentsHumansMaleFemaleMiddle AgedBiomarkersEchocardiographyAgedAdultTime FactorsFollow-Up StudiesNeoplasmsJapan

Stichwörter der Autor:innen

Cardiac diastolic dysfunctionCardio-oncologyCardiotoxicity

Substanzen

Natriuretic Peptide, BrainAnthracyclinesBiomarkersAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Fukushima Medical University.
  • Department of Community Cardiovascular Medicine, Fukushima Medical University.
  • Department of Clinical Laboratory Sciences, Fukushima Medical University.

Zitieren

APA

Tani, T., Oikawa, M., Ohara, H., Yaegashi, D., Sato, Y., Yokokawa, T., Miura, S., Misaka, T., Yoshihisa, A., Ishida, T., & Takeishi, Y. (2025). Subclinical B-type Natriuretic Peptide Elevation 24 Months After Anthracycline-Containing Chemotherapy. International Heart Journal. https://doi.org/10.1536/ihj.24-293

Vancouver

Tani T, Oikawa M, Ohara H, Yaegashi D, Sato Y, Yokokawa T, et al. Subclinical B-type Natriuretic Peptide Elevation 24 Months After Anthracycline-Containing Chemotherapy. International Heart Journal. 2025. doi:10.1536/ihj.24-293

BibTeX
@article{Tani2025,
  author = {Tani, Tetsuya and Oikawa, Masayoshi and Ohara, Himika and Yaegashi, Daiki and Sato, Yu and Yokokawa, Tetsuro and Miura, Shunsuke and Misaka, Tomofumi and Yoshihisa, Akiomi and Ishida, Takafumi and Takeishi, Yasuchika},
  title = {Subclinical B-type Natriuretic Peptide Elevation 24 Months After Anthracycline-Containing Chemotherapy},
  journal = {International Heart Journal},
  year = {2025},
  doi = {10.1536/ihj.24-293}
}
Kostenlos starten →